International Journal of Cardiology
Volume 129, Issue 3 , Pages 309-317 , 13 October 2008

The role of the lymphatic circulation in the natural history and expression of cardiovascular disease

Received 8 July 2007 ,Revised 19 November 2007 ,Accepted 9 February 2008.

References 

  1. Oliver G, Alitalo K. The lymphatic vasculature: recent progress and paradigms. Annu Rev Cell Dev Biol. 2005;21:457–483
  2. Shin WS, Szuba A, Rockson SG. Animal models for the study of lymphatic insufficiency. Lymphat Res Biol. 2003;1(2):159–169
  3. Nakamura K, Rockson SG. Biomarkers of lymphatic function and disease: state of the art and future directions. Mol Diagn Ther. 2007;11(4):227–238
  4. Mehlhorn U, Geissler HJ, Laine GA, Allen SJ. Myocardial fluid balance. Eur J Cardiothorac Surg. 2001;20(6):1220–1230
  5. Santos AC, de Lima JJ, Botelho MF, et al. Cardiac lymphatic dynamics after ischemia and reperfusion–experimental model. Nucl Med Biol. 1998;25(7):685–688
  6. Yoffey JM, Courtice FC. Lymphatics, lymph and the lymphomyeloid complex. New York: Academic Press; 1970;London
  7. Laine GA, Allen SJ. Left ventricular myocardial edema. Lymph flow, interstitial fibrosis, and cardiac function. Circ Res. 1991;68(6):1713–1721
  8. Mehlhorn U, Davis KL, Laine GA, Geissler HJ, Allen SJ. Myocardial fluid balance in acute hypertension. Microcirculation. 1996;3(4):371–378
  9. Stewart RH, Geissler HJ, Allen SJ, Laine GA. Protein washdown as a defense mechanism against myocardial edema. Am J Physiol Heart Circ Physiol. 2000;279(4):H1864–1868
  10. Tabibiazar R, Cheung L, Han J, et al. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med. 2006;3(7):e254
  11. Predescu D, Predescu S, McQuistan T, Palade GE. Transcytosis of alpha1-acidic glycoprotein in the continuous microvascular endothelium. Proc Natl Acad Sci U S A. 1998;95(11):6175–6180
  12. Cooke CJ, Nanjee MN, Stepanova IP, Olszewski WL, Miller NE. Variations in lipid and apolipoprotein concentrations in human leg lymph: effects of posture and physical exercise. Atherosclerosis. 2004;173(1):39–45
  13. Schmeisser A, Christoph M, Augstein A, et al. Apoptosis of human macrophages by Flt-4 signaling: implications for atherosclerotic plaque pathology. Cardiovasc Res. 2006;71(4):774–784
  14. Enholm B, Karpanen T, Jeltsch M, et al. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res. 2001;88(6):623–629
  15. Szuba A, Skobe M, Karkkainen MJ, et al. Therapeutic lymphangiogenesis with human recombinant VEGF-C. Faseb J. 2002;16(14):1985–1987
  16. Geng YJ, Libby P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am J Pathol. 1995;147(2):251–266
  17. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 1990;82(3 Suppl):II38–46
  18. Nakano T, Nakashima Y, Yonemitsu Y, et al. Angiogenesis and lymphangiogenesis and expression of lymphangiogenic factors in the atherosclerotic intima of human coronary arteries. Hum Pathol. 2005;36(4):330–340
  19. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation. 2001;103(18):2283–2288
  20. Lentsch AB, Ward PA. Regulation of inflammatory vascular damage. J Pathol. 2000;190(3):343–348
  21. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138(5 Pt 2):S419–420
  22. Eliska O, Eliskova M, Miller AJ. The absence of lymphatics in normal and atherosclerotic coronary arteries in man: a morphologic study. Lymphology. 2006;39(2):76–83
  23. Rauramaa R, Halonen P, Vaisanen SB, et al. Effects of aerobic physical exercise on inflammation and atherosclerosis in men: the DNASCO Study: a six-year randomized, controlled trial. Ann Intern Med. 2004;140(12):1007–1014
  24. Gloviczki P, Solti F, Szlavy L, Jellinek H. Ultrastructural and electrophysiologic changes of experimental acute cardiac lymphostasis. Lymphology. 1983;16(3):185–192
  25. Sun SC, Lie JT. Cardiac lymphatic obstruction: ultrastructure of acute-phase myocardial injury in dogs. Mayo Clin Proc. 1977;52(12):785–792
  26. Taira A, Uehara K, Fukuda S, Takenada K, Koga M. Active drainage of cardiac lymph in relation to reduction in size of myocardial infarction: an experimental study. Angiology. 1990;41(12):1029–1036
  27. Dellsperger KC, Clothier JL, Hartnett JA, Haun LM, Marcus ML. Acceleration of the wavefront of myocardial necrosis by chronic hypertension and left ventricular hypertrophy in dogs. Circ Res. 1988;63(1):87–96
  28. Solti F, Lengyel E, Jellinek H, Schneider F, Juhasz-Nagy A, Kekesi V. Coronary arteriopathy after lymphatic blockade: an experimental study in dogs. Lymphology. 1994;27(4):173–180
  29. Stolyarov VV, Lushnikova EL, Zuevskii VP, Usynin AF. Morphometric analysis of the lymph system in rat heart during myocardial infarction. Bull Exp Biol Med. 2002;134(2):203–205
  30. Ishikawa Y, Akishima-Fukasawa Y, Ito K, et al. Lymphangiogenesis in myocardial remodelling after infarction. Histopathology. 2007;51(3):345–353
  31. Rockson SG. Lymphedema. Am J Med. 2001;110(4):288–295
  32. Kong D, Kong X, Wang L. Effect of cardiac lymph flow obstruction on cardiac collagen synthesis and interstitial fibrosis. Physiol Res. 2006;55(3):253–258
  33. Maclean D, Fishbein MC, Maroko PR, Braunwald E. Hyaluronidase-induced reductions in myocardial infarct size. Science (New York, NY. 1976;194(4261):199–200
  34. Yotsumoto G, Moriyama Y, Yamaoka A, Taira A. Experimental study of cardiac lymph dynamics and edema formation in ischemia/reperfusion injury — with reference to the effect of hyaluronidase. Angiology. 1998;49(4):299–305
  35. Maroko PR, Hillis LD, Muller JE, et al. Favorable effects of hyaluronidase on electrocardiographic evidence of necrosis in patients with acute myocardial infarction. N Engl J Med. 1977;296(16):898–903
  36. Cairns JA, Holder DA, Tanser P, Missirlis E. Intravenous hyaluronidase therapy for myocardial infarction in man: double-blind trial to assess infarct size limitation. Circulation. 1982;65(4):764–771
  37. Roberts R, Braunwald E, Muller JE, et al. Effect of hyaluronidase on mortality and morbidity in patients with early peaking of plasma creatine kinase MB and non-transmural ischaemia. Multicentre investigation for the limitation of infarct size (MILIS). Br Heart J. 1988;60(4):290–298
  38. MILIS Study Group. Hyaluronidase therapy for acute myocardial infarction: results of a randomized, blinded, multicenter trial. Am J Cardiol. 1986;57(15):1236–1243
  39. Saltissi S, Robinson PS, Coltart DJ, Webb-Peploe MM, Croft DN. Effects of early administration of a highly purified hyaluronidase preparation (GL enzyme) on myocardial infarct size. Lancet. 1982;1(8277):867–871
  40. Repa I, Garnic JD, Hollenberg NK. Myocardial infarction treated with two lymphagogues, calcium dobesilate (CLS 2210) and hyaluronidase: a coded, placebo-controlled animal study. J Cardiovasc Pharmacol. 1990;16(2):286–291
  41. Allen SJ, Geissler HJ, Davis KL, et al. Augmenting cardiac contractility hastens myocardial edema resolution after cardiopulmonary bypass and cardioplegic arrest. Anesth Analg. 1997;85(5):987–992
  42. Pratt JW, Schertel ER, Schaefer SL, et al. Acute transient coronary sinus hypertension impairs left ventricular function and induces myocardial edema. Am J Physiol. 1996;271(3 Pt 2):H834–841
  43. Rubboli A, Sobotka PA, Euler DE. Effect of acute edema on left ventricular function and coronary vascular resistance in the isolated rat heart. Am J Physiol. 1994;267(3 Pt 2):H1054–1061
  44. Kong XQ, Wang LX, Kong DG. Cardiac lymphatic interruption is a major cause for allograft failure after cardiac transplantation. Lymphat Res Biol. 2007;5(1):45–47
  45. Slater JP, Amirhamzeh MM, Yano OJ, et al. Discriminating between preservation and reperfusion injury in human cardiac allografts using heart weight and left ventricular mass. Circulation. 1995;92(9 Suppl):II223–II227
  46. Hosenpud JD, Norman DJ, Cobanoglu MA, Floten HS, Conner RM, Starr A. Serial echocardiographic findings early after heart transplantation: evidence for reversible right ventricular dysfunction and myocardial edema. J Heart Transplant. 1987;6(6):343–347
  47. Baddoura FK, Nasr IW, Wrobel B, Li Q, Ruddle NH, Lakkis FG. Lymphoid neogenesis in murine cardiac allografts undergoing chronic rejection. Am J Transplant. 2005;5(3):510–516
  48. Weis M, von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation. 1997;96(6):2069–2077
  49. Johnsson C, Hallgren R, Elvin A, Gerdin B, Tufveson G. Hyaluronidase ameliorates rejection-induced edema. Transpl Int. 1999;12(4):235–243
  50. Geissler HJ, Dashkevich A, Fischer UM, et al. First year changes of myocardial lymphatic endothelial markers in heart transplant recipients. Eur J Cardiothorac Surg. 2006;29(5):767–771
  51. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999;144(4):789–801
  52. Prevo R, Banerji S, Ferguson DJ, Clasper S, Jackson DG. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem. 2001;276(22):19420–19430
  53. Jackson DG. Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. Apmis. 2004;112(7–8):526–538
  54. Ji RC. Lymphatic endothelial cells, lymphangiogenesis, and extracellular matrix. Lymphat Res Biol. 2006;4(2):83–100
  55. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell. 1999;98(6):769–778
  56. Wigle JT, Harvey N, Detmar M, et al. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J. 2002;21(7):1505–1513
  57. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005;65(3):550–563
  58. Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell. 2002;3(3):411–423
  59. Kriehuber E, Breiteneder-Geleff S, Groeger M, et al. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J Exp Med. 2001;194(6):797–808
  60. Hirakawa S, Hong YK, Harvey N, et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol. 2003;162(2):575–586
  61. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U S A. 1998;95(1):258–263
  62. Ebata N, Nodasaka Y, Sawa Y, et al. Desmoplakin as a specific marker of lymphatic vessels. Microvasc Res. 2001;61(1):40–48
  63. Kriederman BM, Myloyde TL, Witte MH, et al. FOXC2 haploinsufficient mice are a model for human autosomal dominant lymphedema–distichiasis syndrome. Hum Mol Genet. 2003;12(10):1179–1185
  64. Petrova TV, Karpanen T, Norrmen C, et al. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med. 2004;10(9):974–981
  65. Kajiya K, Hirakawa S, Ma B, Drinnenberg I, Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J. 2005;24(16):2885–2895
  66. Huang XZ, Wu JF, Ferrando R, et al. Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. Mol Cell Biol. 2000;20(14):5208–5215
  67. Petrova TV, Makinen T, Makela TP, et al. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. Embo J. 2002;21(17):4593–4599
  68. Irjala H, Johansson EL, Grenman R, Alanen K, Salmi M, Jalkanen S. Mannose receptor is a novel ligand for l-selectin and mediates lymphocyte binding to lymphatic endothelium. J Exp Med. 2001;194(8):1033–1042
  69. Yuan L, Moyon D, Pardanaud L, et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development (Cambridge, England). 2002;129(20):4797–4806
  70. Ayadi A, Zheng H, Sobieszczuk P, et al. Net-targeted mutant mice develop a vascular phenotype and up-regulate egr-1. EMBO J. 2001;20(18):5139–5152
  71. Harvey NL, Srinivasan RS, Dillard ME, et al. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat Genet. 2005;37(10):1072–1081
  72. Schacht V, Ramirez MI, Hong YK, et al. T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. Embo J. 2003;22(14):3546–3556
  73. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999;154(2):385–394
  74. Pennisi D, Gardner J, Chambers D, et al. Mutations in Sox18 underlie cardiovascular and hair follicle defects in ragged mice. Nat Genet. 2000;24(4):434–437
  75. Abtahian F, Guerriero A, Sebzda E, et al. Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science (New York, NY). 2003;299(5604):247–251
  76. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997;276(5317):1423–1425
  77. Karkkainen MJ, Haiko P, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2004;5(1):74–80
  78. Dumont DJ, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science. 1998;282(5390):946–949
  79. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 1995;92(8):3566–3570
  80. Karkkainen MJ, Saaristo A, Jussila L, et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A. 2001;98(22):12677–12682
  81. Rockson SG. The lymphatic continuum continues. Lymphat Res Biol. 2006;4(1):1–2
  82. Kerjaschki D, Huttary N, Raab I, Regele H, Bojarski-Nagy K, Bartel G, et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat Med. 2006;12(2):230–234
  83. Kerjaschki D, Regele HM, Moosberger I, Nagy-Bojarski K, Watschinger B, Soleiman A, et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol. 2004;15(3):603–612
  84. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48(6):2545–2552

PII: S0167-5273(08)00434-8

doi: 10.1016/j.ijcard.2008.02.007

International Journal of Cardiology
Volume 129, Issue 3 , Pages 309-317 , 13 October 2008

Article Tools

* Image Usage & Resolution